Basic and diluted earnings (loss) per share attributable to Teva’s ordinary shareholders for the three and nine months ended September 30, 2026 and 2025, are calculated as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | | September 30, | | September 30, | | | (U.S. $ in millions except share and per share data) | | | 2026 | | 2025 | | 2026 | | 2025 | | Basic earnings (loss) attributable to Teva’s ordinary shareholders (numerator): | | | | | | | | | | Net income (loss) attributable to Teva’s ordinary shareholders | | $ | 233 | | | $ | 433 | | | $ | 26 | | | $ | 930 | | | Shares (denominator): | | | | | | | | | | Weighted average shares outstanding | | 1,166 | | | 1,147 | | | 1,162 | | | 1,144 | | | Basic earnings (loss) attributable to Teva’s ordinary shareholders | | $ | 0.20 | | | $ | 0.38 | | | $ | 0.02 | | | $ | 0.81 | | | | | | | | | | | | Diluted earnings (loss) attributable to Teva’s ordinary shareholders (numerator): | | | | | | | | | | Net income (loss) attributable to Teva’s ordinary shareholders | | $ | 233 | | | $ | 433 | | | $ | 26 | | | $ | 930 | | | Shares (denominator): | | | | | | | | | | Weighted average shares outstanding | | 1,166 | | | 1,147 | | | 1,162 | | | 1,144 | | | Diluted effect of stock options, RSUs and PSUs | | 17 | | | 17 | | | 18 | | | 16 | | | Total dilutive shares outstanding | | 1,183 | | | 1,164 | | | 1,180 | | | 1,160 | | | Diluted earnings (loss) attributable to Teva’s ordinary shareholders | | $ | 0.20 | | | $ | 0.37 | | | $ | 0.02 | | | $ | 0.80 | |
|